CAR T-Cell Therapy

 

Personalized treatment for cancer reached a new milestone with the FDA approval of CAR T cells for treatment of leukemia and lymphoma.  There is now rapid growth in research on the therapeutic uses of CAR T cells.

A therapeutic CAR (chimeric antigen receptor) is a transmembrane protein designed with an extracellular domain based on an antibody single-chain variable fragment (scFv) and intracellular signaling domains derived from the TCR g chain along with other costimulatory receptors.  The scFv provides a specific binding domain to target proteins on cancer cells.  A patents own T cells are isolated and activated and then transfected with a gene expressing the CAR.  This creates personalized immune cells designed to treat the patents cancer.

The first FDA approved treatments were of CAR T cells targeted the B cell protein CD19.  These CAR T cells are a durable treatment option for cancers that are otherwise unmanageable.

Success with CD19 inspires new research on targets for both blood cancer and even solid tumors.  For example, BCMA and CD22 are promising targets in early clinical trials of CAR-T treatment for multiple myeloma and acute lymphoblastic leukemia.  CD19 targeting CAR T cells are also in development as co-therapies to therapeutic antibodies targeting the PD-1:PD-L1 and CD28:CTLA4 pathways.  The aim of these early studies are to determine if CAR T cells can overcome the challenges of adaptive resistance to immune checkpoint therapies. At BPS Bioscience, we strive to provide tools for the cutting edge of cancer research. We are producing a growing list of experimental cell lines and recombinant proteins to help the search for new CAR T cell therapies.  Contact us to find out how we can help with your research needs.

Items 1 to 25 of 28 total

per page
Page:
  1. 1
  2. 2

Catalog#SizeProduct NamePrice
79500-H 2 vials BCMA CHO Recombinant Cell Line (High Expression)
$5,500
79500-L 2 vials BCMA CHO Recombinant Cell Line (Low Expression)
$5,500
79500-M 2 vials BCMA CHO Recombinant Cell Line (Medium Expression)
$5,500
79467 50 μg BCMA, Fc-fusion (IgG1), Avi-Tag, Biotin-Labeled HiP™
$420
79465 100 µg BCMA, Fc-Fusion, Avi-Tag HiP™
$310
100068 50 µg CD123, Fc-Fusion (IgG1) Avi-Tag, Biotin-Labeled
$420
79472 100 μg CD19, Fc-Fusion (IgG1), Avi-Tag
$310
79475 50 μg CD19, Fc-Fusion (IgG1), Avi-Tag, Biotin-Labeled
$420
79464 100 μg CD22, Fc-fusion, Avi-Tag HiP™
$315
79466 50 μg CD22, Fc-fusion, Avi-Tag, Biotin-labeled HiP™
$420
72511 50 μg CD30, Fc-Fusion (IgG1), Avi-Tag, Biotin-Labeled
$420
71277 100 μg CD38, His-Tag (Human), HiP™
$315
79070 100 μg CD38, His-Tag (Mouse), HiP™
$310
71883 100 μg CD38-APC, His-Tag
$310
79118 100 μg CD47 (Monkey), Fc Fusion (Human), Avi-Tag HiP™
$310
79302 50 μg CD47 (Monkey), Fc Fusion (Human), Avi-Tag, Biotin HiP™
$420
71249 2 vials CD47 - HEK293 Cell Line
$5,775
60602 2 vials CD47 CHO-K1 Cell line
$3,850
71177 100 µg CD47, Fc fusion (Human) HiP™
$315
79051 100 µg CD47, Fc fusion, Avi-Tag (Human) HiP™
$310
72514 50 μg CD47, Fc Fusion, Avi-Tag, Biotin-Labeled (Mouse)
$420
71169 50 μg CD47, Fc fusion, Biotin-labeled (Human) HiP™
$420
71292 100 µg CD47, Fc-Fusion, Streptavidin-Labeled (Human) HiP™
$310
71127 100 µg CD47, His-tag (Human)
$315
60543 2 vials PD-L1 - CHO Recombinant Cell Line
$3,750

Items 1 to 25 of 28 total

per page
Page:
  1. 1
  2. 2